Biotech Values

[mcbio]

It would help if you could clarify what you mean by more share in this context. More than what, exactly?

Did you read #msg-56388251? Comments?

MNTA likely can't comfortably afford a 10,000 to 15,000 patient Phase 3 trial for M118. And MNTA has yet to find a partner for M118 presumably due to such prohibitive expenses. So, how about some arrangement where MNTA agrees to fund a portion of the costs of Phase 3 trials (say 25%) with the partner taking on the rest and the two parties pro-rating the split of any potential revenues accordingly.